発作性夜間ヘモグロビン尿症（PNH）の成人患者を対象とした、ポゼリマブとセムジシランの併用療法による長期治療の安全性と有効性を評価する研究

基本情報

NCT ID

NCT05744921

ステータス

募集中

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

202

治験依頼者名

Regeneron Pharmaceuticals

概要

This study is researching an experimental treatment combination with two experimental drugs called pozelimab and cemdisiran. The study is focused on people with paroxysmal nocturnal hemoglobinuria (PNH). The aim of this study is to see how safe and effective the pozelimab + cemdisiran combination is for people with PNH in the long term. The pozelimab + cemdisiran combination may be referred to as "study drugs" in this section. This study is looking at several other research questions, including: * How effective is the pozelimab + cemdisiran combination? * What side effects may happen from taking the study drugs? * How much of each study drug is in the blood at different times? * Whether the body makes antibodies against the study drugs (which could make the drugs less effective or could lead to side effects)

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)